Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Presatovir - Gilead Sciences

Next Previous
Drug Profile

Presatovir - Gilead Sciences

Alternative Names: GS-5806

Latest Information Update: 24 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antivirals; Chlorinated hydrocarbons; Piperidines; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 24 Sep 2020 No development reported - Phase-II for Respiratory syncytial virus infections (In the elderly, In adults) in Taiwan, Brazil, Spain, Sweden, Switzerland, Singapore, Germany, Poland, Netherlands, South Korea, Italy, Israel, Belgium, USA, France, New Zealand, Australia, United Kingdom, Canada (PO) (Gilead Sciences website, September 2020)
  • 18 May 2018 Safety and efficacy data from a phase IIb trial in Respiratory syncytial virus infections presented at the 114th International Conference of the American Thoracic Society (AST-2018)
  • 27 Sep 2017 Gilead Sciences completes a phase II trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, Belgium, Canada, Australia, France, Germany, Netherlands and United Kingdom (PO) (NCT02534350)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top